1. Pink Sheet
  2. >>Regulatory Trackers

US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’

 
• By Sarah Karlin-Smith

Expert panels may be used to help the FDA decide when and how a new biomarker could be leveraged for regulatory purposes. Participants at workshop on allergy and asthma biomarkers also discuss need for standardization of food allergy trials and new trial design approaches. 

blurred image of people meeting around a oval shaped table
Advisory committees may help FDA decide the utility of biomarkers for allergy and asthma drug development programs • Source: Shutterstock

The US Food and Drug Administration will likely bring any promising biomarkers for allergy and asthma treatments to an advisory committee review before endorsing their use for regulatory purposes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers